BIOMAT Database Logo BIOMAT Database Logo

Combination chemotherapy of carboplatin and cytosine arabinoside for high-risk leukemia: a pilot study. 1995

N Iwao, and M Yoshida, and K Hatake, and Y Hoshino, and S Hagiwara, and H Tomizuka, and R Shimizu, and T Suzuki, and Y Furukawa, and N Komatsu
Department of Medicine, Jichi Medical School, Tochigi, Japan.

Fourteen patients with high-risk leukemia (six with relapsed AML, three with relapsed ALL, one with AML-M0, four with CML in myeloid blastic crisis) were treated with a combination chemotherapy of carboplatin (200-300 mg/m2/day) and cytosine arabinoside (100 mg/m2/day) by 24 h continuous infusion for 5-7 days. Five patients (35.7%) achieved complete remission including two patients complicated with myelofibrosis (one with AML-M0 and one with CML in myelo-megakaryocytic crisis). Thirteen patients had nausea and vomiting, five patients had severe, prolonged neutropenia for which it was necessary to administer granulocyte colony-stimulating factor and six patients had severe thrombocytopenia. We concluded that this regimen is effective for the treatment of high-risk leukemia.

UI MeSH Term Description Entries
D007938 Leukemia A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006) Leucocythaemia,Leucocythemia,Leucocythaemias,Leucocythemias,Leukemias
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009503 Neutropenia A decrease in the number of NEUTROPHILS found in the blood. Neutropenias
D010865 Pilot Projects Small-scale tests of methods and procedures to be used on a larger scale if the pilot study demonstrates that these methods and procedures can work. Pilot Studies,Pilot Study,Pilot Project,Project, Pilot,Projects, Pilot,Studies, Pilot,Study, Pilot
D012074 Remission Induction Therapeutic act or process that initiates a response to a complete or partial remission level. Induction of Remission,Induction, Remission,Inductions, Remission,Remission Inductions
D003561 Cytarabine A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472) Ara-C,Arabinofuranosylcytosine,Arabinosylcytosine,Cytosine Arabinoside,Aracytidine,Aracytine,Cytarabine Hydrochloride,Cytonal,Cytosar,Cytosar-U,beta-Ara C,Ara C,Arabinoside, Cytosine,Cytosar U,beta Ara C
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths

Related Publications

N Iwao, and M Yoshida, and K Hatake, and Y Hoshino, and S Hagiwara, and H Tomizuka, and R Shimizu, and T Suzuki, and Y Furukawa, and N Komatsu
Conventional dose cytosine arabinoside in combination chemotherapy for acute myelogenous leukemia.
June 1987, Seminars in oncology,
N Iwao, and M Yoshida, and K Hatake, and Y Hoshino, and S Hagiwara, and H Tomizuka, and R Shimizu, and T Suzuki, and Y Furukawa, and N Komatsu
[Combination chemotherapy with cytosine arabinoside and daunomycin in childhood acute leukemia].
May 1973, [Rinsho ketsueki] The Japanese journal of clinical hematology,
N Iwao, and M Yoshida, and K Hatake, and Y Hoshino, and S Hagiwara, and H Tomizuka, and R Shimizu, and T Suzuki, and Y Furukawa, and N Komatsu
Combination amsacrine and high-dose cytosine arabinoside in acute leukemia.
January 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
N Iwao, and M Yoshida, and K Hatake, and Y Hoshino, and S Hagiwara, and H Tomizuka, and R Shimizu, and T Suzuki, and Y Furukawa, and N Komatsu
Etoposide and cytosine arabinoside combination chemotherapy for refractory acute lymphocytic leukemia in childhood.
July 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
N Iwao, and M Yoshida, and K Hatake, and Y Hoshino, and S Hagiwara, and H Tomizuka, and R Shimizu, and T Suzuki, and Y Furukawa, and N Komatsu
[Combination of AMSA-high dose cytosine arabinoside in acute leukemia].
June 1985, Presse medicale (Paris, France : 1983),
N Iwao, and M Yoshida, and K Hatake, and Y Hoshino, and S Hagiwara, and H Tomizuka, and R Shimizu, and T Suzuki, and Y Furukawa, and N Komatsu
Chemotherapy for colorectal cancer with a combination of 5-fluorouracil, mitomycin C, adriamycin, and cytosine arabinoside: a pilot study.
October 1978, Cancer treatment reports,
N Iwao, and M Yoshida, and K Hatake, and Y Hoshino, and S Hagiwara, and H Tomizuka, and R Shimizu, and T Suzuki, and Y Furukawa, and N Komatsu
Cytosine arabinoside chemotherapy for acute megakaryocytic leukemia in a cat.
August 1991, Journal of the American Veterinary Medical Association,
N Iwao, and M Yoshida, and K Hatake, and Y Hoshino, and S Hagiwara, and H Tomizuka, and R Shimizu, and T Suzuki, and Y Furukawa, and N Komatsu
Combination chemotherapy with daunorubicin, cytosine arabinoside and prednisolone (DAP) in acute nonlymphocytic leukemia.
July 1981, Nihon Ketsueki Gakkai zasshi : journal of Japan Haematological Society,
N Iwao, and M Yoshida, and K Hatake, and Y Hoshino, and S Hagiwara, and H Tomizuka, and R Shimizu, and T Suzuki, and Y Furukawa, and N Komatsu
VM-26 and cytosine arabinoside combination chemotherapy for initial induction failures in childhood lymphocytic leukemia.
October 1980, Cancer,
N Iwao, and M Yoshida, and K Hatake, and Y Hoshino, and S Hagiwara, and H Tomizuka, and R Shimizu, and T Suzuki, and Y Furukawa, and N Komatsu
VP 16-213 and cytosine-arabinoside combination chemotherapy for refractory acute lymphoblastic leukemia in adults.
December 1984, European journal of cancer & clinical oncology,
Copied contents to your clipboard!